811 material Form 8-K filings that 685 companies we cover made with the SEC in April 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Constellation Brands and its subsidiary CB International Finance entered into a restatement of their credit agreement with Bank of America as administrative agent. The $2.25 billion senior unsecured revolving credit facility was refinanced and its maturity extended to April 28, 2030, and the general liens basket was increased from 7.5% to 10.0% of consolidated tangible assets. The filing describes a new direct financial obligation, but it does not state a change in borrowing amount, and it contains no financial results.
Revolving credit facility: $2.25 billion of aggregate commitments refinanced under the Eleventh Restated Credit Agreement
Maturity extended from the prior agreement to April 28, 2030
General liens basket increased from 7.5% to 10.0% of consolidated tangible assets
Company unconditionally guarantees CB International Finance's obligations under the agreement
Cigna entered a $6.5 billion five-year revolving credit agreement dated April 24, 2025, which replaces its existing revolving facilities and terminates its $5.0 billion agreement dated April 25, 2024. Separately, Executive Vice President and Global Chief Information Officer Noelle Eder resigned effective May 16, 2025, for personal reasons, and shareholders at the April 23, 2025 annual meeting elected all eleven director nominees.
New $6.5 billion revolving credit agreement, dated April 24, 2025, for general corporate purposes, with up to $500 million for letters of credit and options to increase commitments by up to $1.5 billion
Leverage ratio covenant of 0.60 to 1.00, or 0.65 to 1.00 for four quarters after an acquisition with cash consideration of $1.0 billion or more
Noelle Eder resigned as EVP and Global Chief Information Officer, effective May 16, 2025, with no disagreement with the company cited
At the annual meeting, 91.04% of shares were represented; a shareholder proposal on special shareholder meetings received 28,117,178 votes for and 200,491,789 against
On April 24, 2025, Semtech amended its credit agreement to raise revolving credit capacity by $117.5 million, to a total of $455 million. The company said no financial covenants or material terms were modified. The company also repaid $10 million of term loan principal from operating cash flow, which it said was unrelated to the amendment, and the filing shows added undrawn borrowing capacity for shareholders.
Revolving credit facility increased by $117.5 million to $455 million under the Fourth Amendment dated April 24, 2025
Facility remains undrawn except for previously outstanding letters of credit totaling $2.9 million
Commitment fee on undrawn amounts was 0.300% as of April 27, 2025, the end of Q1 fiscal 2026
$10 million of term loan principal prepaid using cash flow from operations
On April 25, 2025, United Therapeutics entered a five-year unsecured revolving credit agreement with Wells Fargo as administrative agent, providing up to $2.5 billion, with an option to increase it by up to $750 million. The company borrowed $200.0 million at closing and used the funds to pay off and terminate its 2022 credit agreement with no early termination penalties. The filing shows a refinancing of existing debt rather than a change in operating results, and the new facility includes leverage and interest coverage covenants and a change-of-control default.
Unsecured revolving credit facility of up to $2.5 billion, maturing five years after closing, with up to two one-year extensions
Borrowed $200.0 million at closing on April 25, 2025, and used the proceeds to repay the 2022 Credit Agreement
2022 Credit Agreement, dated March 31, 2022, paid off and terminated with no early termination penalties
Covenants require total indebtedness to EBITDA of no more than 3.50 to 1.00 and interest coverage of at least 3.00 to 1.00
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.